SEC Form 4 · accession 0001104659-16-089386
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Uli Hacksell
Officer — CEO and President · Director
Period of report
Jan 1, 2016
Accepted (ET)
Jan 12, 2016 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.35 | Jan 1, 2016 | A | 360,459 | A | — | Dec 31, 2025 | Common Stock | 360,459 | 388,780 | D |
Explanation of responses
- F1One third of the shares subject to the stock option will vest on January 1, 2017, and the remaining two thirds of the shares subject to the stock option will vest in equal monthly installments over the following 24 months.